Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase-1 Trial to Investigate the Use of Pulsed Low-dose Rate Radiotherapy in Diffuse Midline Gliomas.
Sponsor: Centro di Riferimento Oncologico - Aviano
Summary
Over the past decades, advances in radiation therapy technology have significantly reduced treatment-related toxicity. In patients with diffuse midline glioma (DMG), these improvements have enhanced the tolerability of radiotherapy but have not improved disease control. Pulsed low-dose-rate radiotherapy (pLDRT) may offer additional advantages by further reducing treatment-related toxicity, preserving tumor vascularization to facilitate the delivery and efficacy of subsequent chemotherapy, and exploiting the low-dose hyper-radiosensitivity phenomenon. To the best of our knowledge, no clinical studies have evaluated pLDRT in patients with DMG. Therefore, the primary objective of this phase I study is to evaluate the tolerability of pLDRT in this predominantly pediatric population and to determine a safe dose level for future clinical investigation.
Key Details
Gender
All
Age Range
0 Years - 100 Years
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2026-05-13
Completion Date
2030-07-15
Last Updated
2026-11-05
Healthy Volunteers
No
Conditions
Interventions
Pulsed Low-Dose-Rate Radiotherapy, pLDRT
The radiotherapy treatment will preferably be delivered using volumetric modulated arc therapy (VMAT) with high-energy photons (6 MV), including 6 MV flattening filter-free (FFF) beams when appropriate. In selected cases, intensity-modulated radiotherapy (IMRT) may be used.
Locations (1)
Centro di Riferimento Oncolgico -IRCCS
Aviano, Pordenone, Italy